CoChat
Sign Up
Cited by 85Adipose Tissue and MetabolismPharmacology and Obesity TreatmentAdipokines, Inflammation, and Metabolic Diseases

Immunohistochemical identification of the β3-adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine

De Matteis, R, Arch, JRS, Petroni, ML, Ferrari, D, Cinti, S, Stock, MJ·2002·International Journal of Obesity
DOI 10.1038/sj.ijo.0802148
Open this paper in CoChat — free account

Abstract

Objectives To investigate whether the beta(3)-adrenoceptor could be identified by immunohistochemistry in intact human white and brown adipocytes and other human tissues, and to investigate the influence of obesity and its treatment with ephedrine and caffeine on the expression of the beta(3)-adrenoceptor in adipocytes.Methods Morbidly obese patients were given a hypoenergetic diet (70% of energy expenditure) and some were also treated with ephedrine and caffeine (20/200 mg, three times daily) for 4 weeks. Adipose tissue and other tissues were taken during surgery. Immunohistochemistry was carried out using a monoclonal antibody raised against the human beta(3)-adrenoceptor.Results Staining was localized to the periphery of cells. All white adipocytes were stained. Those from lean subjects and obese subjects treated with ephedrine and caffeine showed more intense staining than those from untreated obese subjects. Staining was more intense in brown than in white adipocytes in perirenal adipose tissue from phaeochromocytoma patients. Staining was also seen in ventricular myocardium, and in smooth muscle of the prostate, ileum, colon and gall bladder.Discussion The tissue and subcellular distribution of staining was consistent with it being due to binding of the antibody to the human beta(3)-adrenoceptor. The presence of the beta(3)-adrenoceptor in human white adipocytes is consistent with evidence that it can mediate lipolysis in human white adipocytes. The increased expression of the beta(3)-adrenoceptor in obese subjects treated with caffeine and ephedrine supports the potential of beta(3)-adrenoceptor agonists in the treatment of obesity and type 2 diabetes. Its expression in ventricular myocardium is consistent with evidence that the beta(3)-adrenoceptor mediates a negative inotropic effect in this tissue.

Integrity signals

Registry

Crossref · 10.1038/sj.ijo.0802148

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The combination of ephedrine and caffeine is a potent mediator of short-term weight loss that likely involves activation of BAT by β3 adrenergic receptors.

    “However, the combination of ephedrine and caffeine is a potent mediator of short-term weight loss 139 that likely involves activation of BAT by β3 adrenergic receptors 140.”

    From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [140]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
De Matteis, R., Arch, J., Petroni, M., Ferrari, D., Cinti, S., & Stock, M.
Affiliations
  • IRCCS Istituto Auxologico Italiano (IT)
  • University of Buckingham (GB)
  • St George's, University of London (GB)
Corresponding author
Cinti, S
ORCID
Cinti, S
Venue
International Journal of Obesity
Publisher
Springer Science and Business Media LLC
Published
2002-11
Volume
26
Issue
11
Pages
1442-1450
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
DOI
10.1038/sj.ijo.0802148
OpenAlex
W2063854776
Cited by
85
References
36
Citations by year
2026: 3 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 1 · 2019: 8 · 2018: 5 · 2016: 8 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 4
FWCI
1.60
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
Keywords
beta3-adrenergic receptor, white adipocytes, brown adipocytes, obesity, ephedrine, caffeine, lipolysis, ventricular myocardium, receptor subcellular distribution, pheochromocytoma, type 2 diabetes, negative inotropic effect, hypocaloric diet
MeSH terms
Adipose Tissue, Adolescent, Adrenergic beta-Agonists, Adult, Caffeine, Ephedrine, Female, Heart Ventricles, Humans, Immunohistochemistry, Male, Myocardium, Obesity, Morbid, Adipocytes, Receptors, Adrenergic, beta-3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review